biotech · Major Depressive Disorder · Alzheimer's Disease · NMRA
Neumora Therapeutics
Neumora Therapeutics is a biotech organization headquartered in copenhagen, DK. It trades on NYSE under ticker NMRA. Primary therapeutic focus areas include Major Depressive Disorder, Alzheimer's Disease, Major Depressiv
copenhagen, DK HQ
18 Employees
Public company Type
NMRA · NYSE Ticker
Company details
- Status
- Public
- HQ
- copenhagen, DK
- Employees
- 18
- Programs
- 5
- Drugs
- 2
- Patents
- 6
NMRA-335140 80 mg
Phase 2 · small molecule · Major Depressive Episode Associated With Bipolar II Disorder
NMRA-335140 80 mg for Major Depressive Episode Associated With Bipolar II Disorder is a Phase 2 program (small_molecule) at Neumora Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code NMRA-335140-202
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Neumora Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Major Depressive Episode Associated With Bipolar II Disorder
- Status
- completed
- Trials
- 1